Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.

Among 17 patients classified in G2 (60–89 mL/min/1.73 m 2 ) and 5 patients classified in G3 (30–59 mL/min/1.73 m 2 ), the eGFR value in one patient showed a trend to worsen from 80.5 mL/min/1.73 m 2 to 22.3 mL/min/1.73 m 2 (60 M), while those of the other 21 patients remained stable from 76.7 mL/min/1.73 m 2 (BL) to 67.8 mL/min/1.73 m 2 (60 M) (Fig. 2a and b ).

also in 53,322 other papers